我们现在在生物药物治疗肌肉炎方面处于什么状态?
Ana Neves1, Luísa Viveiros2, Veronica Venturelli3
1Internal Medicine Department, Centro Hospitalar Universitário de São João, Oporto, Portugal.
Rheumatology (Oxford, England)
|February 6, 2024
概括
新的生物疗法在治疗罕见的自身免疫性疾病 - - 异形性炎症性肌肉病 (IIM) 方面表现有前途. 新兴治疗方法正在临床试验中进行评估,以解决未满足的需求并改善患者的治疗结果.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 异形性炎症性肌肉病变 (IIM) 是一种罕见的慢性自身免疫性疾病,具有显著的长期残疾.
- 目前的管理选择有限,只有IVIG获得批准,很少有生物药物显示有效性.
- 临床试验的挑战包括患者数量少和疾病表现多样化.
研究的目的:
- 审查IIM的新兴生物疗法.
- 评估新疗法在解决未满足的临床需求方面的潜力.
- 突出IIM治疗策略的最新进展.
主要方法:
- 对IIM生物疗法的当前文献的审查.
- 对新生物药物II期随机对照试验数据的分析.
- 评估新型治疗剂的疗效和安全性概况.
主要成果:
- 几种新型生物药物正在研究中,包括B细胞枯竭疗法,阿巴切,JAK抑制剂和aldesleukin.
- 第二阶段试验表明,对IIM患者的临床和实验室测量有潜在的改善.
- 一些生物制剂,如Rituximab,对耐火病例显示出希望,尽管尚未获得批准.
结论:
- 新兴的生物疗法为管理IIM提供了新的希望.
- 持续的研究和临床试验对于开发有效的治疗方法至关重要.
- 了解IIM病原学的进步正在推动针对性治疗的发展.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Myasthenia Gravis: Diagnostic Tests
844
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
844
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120


